Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024...
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc...
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for...
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla...
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal...
AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update Company continues progress across...
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with...
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s...
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi®...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents Extends certain exclusive U.S...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관